The transdermal drug delivery systems market is expected to reach USD 8.6 billion by 2027 from an estimated USD 6.26 billion in 2020, at a CAGR of 4.9 % during the forecast period. Transdermal drug delivery is gathering steam as an advanced drug delivery method, especially for administering macromolecules.
Several advantages they have over parenteral routes account for the growing popularity of products in the transdermal drug delivery market. Clinicians aiming at improving the pharmacokinetic profiles of drugs find this delivery route a fit, in addition to non-invasiveness of the methodology. This aside, the market is seeing investment by pharmaceutical companies who see potential of the method in improving the patient compliance. A large avenue comes from vaccine manufacturers. Epidermal layers prove to be clinically unique in paving way to an efficient vaccination route for administering therapeutic proteins and peptides. The scope is considerably expanded by the drive among healthcare providers and governments, especially in the developing world, to find cost-effective and needle-free options for vaccination process. The large surface of the skin presents itself to incredible scope for utilizing transdermal drug delivery methods. A growing body of research has continuously expanded scientists’ understanding of kinetics of skin permeation, expanding the horizon for players in the transdermal drug delivery market. The kinetics pertains to percutaneous absorption of the drug molecules. Advent of promising physical and chemical methods is expanding the potential of transdermal patches for drug delivery.
The transdermal drug delivery market is driven by the introduction of easy-to-use and effective transdermal drug delivery systems based on cutting-edge technology. The transdermal drug delivery market is increasing due to its rising demand as it is more convenient than conventional systems for administrating drugs. For example, patients that are fanatical to oral drug dosages or those patients in unconscious state can be administered drugs through the transdermal route.
Transdermal patches provide improved control over toxicity levels as these patches can be easily peeled off if the drug is scrutinized to render higher toxic effects. Drug permeation can be monitored and estimated more effectively through this method, which makes it convenient to maintain a constant level of drug serum. In view of these factors, the adoption rate of products in the global transdermal drug delivery market is high. By application, the global transdermal drug delivery market can be classified as hormone replacement therapy, pain management, contraception, neurological disorders, and smoking cessation. Transdermal drug delivery system is one of the fastest growing segments of the total drug delivery sector as it is the most convenient drug delivery system.
The key players in the transdermal drug delivery systems market are Hisamitsu Pharmaceutical (Japan), Mylan (US), UCB (Belgium), Novartis (Switzerland), and GlaxoSmithKline (UK). Boehringer Ingelheim (Germany), Johnson & Johnson (US), Endo International (Ireland), and Purdue Pharma (US).
North America is one of the major revenue generating regions in the transdermal drug delivery systems market. The transdermal drug delivery systems market in the region is driven by the rising prevalence of targeted diseases (such as chronic pain, central nervous system disorders, and cardiovascular diseases) in the region, the increasing use of contraceptives, and the increasing number of research activities related to transdermal drug delivery systems.
The Asia Pacific market is anticipated to exhibit the fastest CAGR during the forecast period, which is attributable to the growing healthcare spending and the rapidly evolving healthcare infrastructure. In addition, the growth is due to the high research and development intensity as well as the growing awareness in the emerging economies, such as China and India.